Novo Nordisk A/S

WBAG:NNO2 Stock Report

Market Cap: €457.6b

Novo Nordisk Valuation

Is NNO2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NNO2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NNO2 (€103.14) is trading below our estimate of fair value (€156.83)

Significantly Below Fair Value: NNO2 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NNO2?

Key metric: As NNO2 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NNO2. This is calculated by dividing NNO2's market cap by their current earnings.
What is NNO2's PE Ratio?
PE Ratio36x
EarningsDKK 94.72b
Market CapDKK 3.41t

Price to Earnings Ratio vs Peers

How does NNO2's PE Ratio compare to its peers?

The above table shows the PE ratio for NNO2 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average39.4x
LLY Eli Lilly
82.3x29.8%US$701.1b
JNJ Johnson & Johnson
23.6x10.6%US$352.5b
MRK Merck
20.5x16.0%US$253.1b
AZN AstraZeneca
31.4x18.2%UK£160.5b
NNO2 Novo Nordisk
36x14.3%€3.4t

Price-To-Earnings vs Peers: NNO2 is good value based on its Price-To-Earnings Ratio (36x) compared to the peer average (40x).

Price to Earnings Ratio vs Industry

How does NNO2's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
NNO2 36.0xIndustry Avg. 19.5xNo. of Companies11PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NNO2 is expensive based on its Price-To-Earnings Ratio (36x) compared to the European Pharmaceuticals industry average (19.7x).

Price to Earnings Ratio vs Fair Ratio

What is NNO2's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NNO2 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio36x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NNO2's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NNO2 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€103.14
€126.67
+22.8%
20.3%€154.16€75.07n/a24
Dec ’25€101.40
€125.78
+24.0%
20.3%€154.20€75.09n/a24
Nov ’25€103.38
€126.61
+22.5%
20.4%€154.14€75.06n/a24
Oct ’25€106.36
€127.43
+19.8%
20.3%€154.25€75.11n/a25
Sep ’25€125.50
€127.40
+1.5%
20.1%€160.79€75.03n/a26
Aug ’25€123.22
€129.40
+5.0%
18.7%€160.81€75.04n/a26
Jul ’25€135.84
€127.68
-6.0%
18.3%€160.91€75.09n/a26
Jun ’25€122.00
€122.99
+0.8%
18.5%€150.17€71.06n/a26
May ’25€117.50
€121.18
+3.1%
19.4%€150.10€71.03n/a25
Apr ’25€121.00
€119.91
-0.9%
19.6%€150.18€71.07n/a25
Mar ’25€114.34
€110.04
-3.8%
16.8%€131.50€71.12n/a24
Feb ’25€105.60
€103.43
-2.1%
18.5%€131.48€60.38n/a23
Jan ’25€93.70
€96.70
+3.2%
20.4%€117.40€48.30n/a23
Dec ’24€93.38
€95.45
+2.2%
20.2%€117.41€48.31€101.4023
Nov ’24€92.20
€91.64
-0.6%
21.1%€110.61€48.27€103.3822
Oct ’24€86.76
€86.99
+0.3%
19.7%€108.61€48.27€106.3622
Sep ’24€87.27
€82.92
-5.0%
18.1%€103.93€48.28€125.5022
Aug ’24€71.54
€78.28
+9.4%
15.8%€97.32€48.33€123.2223
Jul ’24€73.14
€77.73
+6.3%
16.2%€97.32€48.32€135.8422
Jun ’24€73.25
€77.15
+5.3%
16.8%€97.36€48.35€122.0022
May ’24€76.11
€75.03
-1.4%
19.5%€97.30€45.63€117.5022
Apr ’24€73.07
€68.52
-6.2%
18.6%€83.19€45.62€121.0022
Mar ’24€66.83
€65.82
-1.5%
17.0%€82.00€45.71€114.3423
Feb ’24€63.18
€63.91
+1.2%
18.3%€80.66€36.30€105.6023
Jan ’24€63.42
€60.43
-4.7%
15.4%€72.92€36.29€93.7023
Dec ’23€60.20
€58.65
-2.6%
15.9%€72.93€36.30€93.3824

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 06:58
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Novo Nordisk A/S is covered by 71 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Kamla SinghAlphaValue
Gerhard SchwarzBaader Helvea Equity Research